Nab-Sirolimus Delivers Durable Responses in PEComa Subgroups
Treatment with nab-Sirolimus demonstrated promising response rates in patients with gynecologic PEComa, according to a subgroup analysis of the phase 2 AMPECT study.
Thomas Herzog, MD
Nab-Sirolimus (Fyarro; ABI-009) delivered rapid and durable responses in patients with perivascular epithelioid sarcoma (PEComa), according to a subgroup analysis of the phase 2 AMPECT study (NCT02494570) presented by Thomas Herzog, MD, at the 2024 Society of Gynecologic Oncology Annual Meeting.1
An overall response rate (ORR) of 37.5% (95% CI, 15.2%-64.6%) among 16 female patients with malignant PEComa in uterine, ovarian, pelvic, and retroperitoneal sites, regardless of TSC1/TSC2 mutation status was observed, and all responses were confirmed partial responses (PRs). Moreover, the disease control rate (DCR) in the subgroup was 62.5%, and 4 of 16 patients (25%) experienced stable disease for at least 12 weeks.
This subgroup comprised over half of the evaluable study population, and the ORR from this analysis was similar to the 38.7% ORR observed in the overall population evaluation. Additionally, the DCR in the overall population was 71%. Among all patients with malignant PEComa, the median duration of response (DOR) was 39.7 months, and the median overall survival (OS) was 53.1 months.
Regarding safety, 100% of patients experienced treatment-related adverse events (TRAEs) of any grade, while 63% of patients had a TRAE of grade 3. The most common any-grade TRAEs were stomatitis (81%), fatigue (63%), edema (56%), maculopapular rash (56%), diarrhea (50%), and nausea (50%). Grade 3 TRAEs included stomatitis (25%), hyperglycemia (13%), hypokalemia (13%), increased amylase (6%), vomiting (6%), and diarrhea (6%). There were no grade 4 or 5 TRAEs observed. TRAEs led to dose delay in 63% of patients, dose reduction in 31%, and treatment discontinuation in 6%.
About the Phase 2 AMPECT Study
The primary end point of the AMPECT study was ORR by independent review, and secondary end points included DOR, DCR, and safety/tolerability. Patients were eligible for enrollment if they were 18 or older, had an ECOG performance status of 0 to 1, had histologically confirmed malignant PEComa, had locally advanced or inoperable metastatic disease, and had not received treatment with a prior mTOR inhibitor.
A total of 16 female patients were evaluated in this subgroup analysis. The median age was 61.5 years (range, 39-78). Nine patients (56%) were White and 3 (19%) were Black. Twelve (75%) patients identified as not Hispanic or Latino. Of the overall population of 31 patients, 7 patients had a disease origin from the uterus, 1 from the ovary, 5 from the retroperitoneum, 3 from the pelvis, and 15 from another.
Patients were treated with 100 mg/m2 of intravenous nab-Sirolimus on days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicity were observed.
About PEComa and the Treatment Landscape
Nab-Sirolimus is the first and only FDA-approved treatment for locally advanced or metastatic malignant unresectable PEComa. The agent was approved in this intent-to-treat population in November 2021.2
Advanced malignant PEComas are associated with poor prognoses and typically demonstrate local invasion or metastases, according to the presentation from Herzog, University of Cincinnati Cancer Center.1 In the metastatic unresectable setting, the median OS ranges from 16 months with chemotherapy to 29 months with targeted therapy. The presence of nab-Sirolimus on the market represents an important treatment option as the standard of care for patients with this rare cancer.
According to Herzog, more studies are underway investigating nab-Sirolimus to treat malignant PEComa mTOR-driven cancers of gynecologic origin.
